SEOUL, South Korea

韩国首尔

,

，

April 22, 2026

2026年4月22日

/PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a next-generation subcutaneous (SC) delivery platform designed to simultaneously enhance the administration convenience and therapeutic efficacy of antibody therapeutics..

/PRENewswire/ -- Prestige Biopharma IDC是Prestige Biopharma的创新药物研究所，该机构宣布已为“IDC224”提交专利申请。这是一种下一代皮下（SC）递送平台，旨在同时提高抗体治疗药物的给药便利性和治疗效果。

While most current antibody therapeutics are administered via intravenous (IV) infusion—typically requiring more than an hour and dedicated medical assistance—subcutaneous (SC) administration offers a rapid, highly convenient alternative for patients. Given the high patient convenience and the mitigation of risks associated with repeated vascular access, the global pharmaceutical and biotechnology industry is witnessing a strategic shift from IV to SC delivery methods..

虽然目前大多数抗体治疗药物都是通过静脉 (IV) 输注给药——通常需要一个多小时并依赖专业的医疗协助——但皮下 (SC) 注射为患者提供了一种快速且高度便捷的替代方案。鉴于其高便利性以及降低了与反复血管通路相关的风险，全球制药和生物技术行业正在经历从静脉输注向皮下注射的战略性转变。

However, antibody therapeutics face significant technical barriers regarding the stable delivery of high-concentration formulations, necessitating advanced engineering for successful SC conversion. Prestige Biopharma IDC has addressed these challenges with the development of its proprietary IDC224 technology..

然而，抗体治疗在高浓度配方的稳定递送方面面临显著的技术障碍，这使得成功实现皮下注射（SC）转换需要先进的工程技术。Prestige Biopharma IDC通过开发其专有的IDC224技术应对了这些挑战。

The IDC224 platform is characterized by a unique liquid-to-gel transition mechanism; the drug is administered in a liquid state and subsequently transforms into a gel upon exposure to body temperature. This process facilitates the sustained release of the drug, effectively extending its therapeutic duration and reducing dosing frequency.

IDC224平台的特点是一种独特的液体到凝胶的转变机制；药物以液态形式给药，随后在接触到体温时转变为凝胶。这一过程促进了药物的持续释放，有效延长了其治疗时间并减少了给药频率。

Furthermore, the platform enables the uniform loading of high-concentration antibodies, thereby maximizing delivery efficiency. It also secures a strong competitive edge in safety by utilizing biocompatible and biodegradable materials..

此外，该平台能够统一加载高浓度抗体，从而最大化递送效率。通过使用生物相容性和可生物降解的材料，该平台在安全性方面也确保了强大的竞争优势。

The project lead overseeing the development of IDC224 stated, 'This platform was engineered to optimize the mode of administration, drug delivery efficiency, and patient convenience in tandem. In pre-clinical studies applying this platform to gastric, ovarian, and breast cancer models, we confirmed improved therapeutic efficacy compared to conventional methods.' The representative added, 'This patent is a follow-up to our existing composition patent and holds significant value as a 'use patent,' which newly defines the anticancer efficacy achieved through this specific composition.'.

负责监督IDC224开发的项目主管表示：“该平台旨在优化给药方式、药物递送效率以及患者便利性。在将该平台应用于胃癌、卵巢癌和乳腺癌模型的临床前研究中，我们确认其相比传统方法具有更好的治疗效果。”该代表补充道：“这项专利是我们现有成分专利的延续，作为一项‘用途专利’，它重新定义了通过这种特定组合实现的抗癌功效，因此具有重要价值。”

Notably, this technology is designed to facilitate the potential SC conversion of Tuznue®, Prestige Biopharma's trastuzumab biosimilar, which is currently approved in Europe in its existing formulation. This technology therefore holds substantial strategic value in further strengthening product competitiveness and enabling future differentiated administration options for patients and healthcare providers..

值得注意的是，该技术旨在促进Prestige Biopharma的曲妥珠单抗生物类似药Tuznue®潜在的皮下注射（SC）转换，该药物目前在欧洲已获批其现有配方。因此，这项技术在进一步提升产品竞争力以及为患者和医疗保健提供者实现未来差异化的给药选择方面具有重要的战略价值。

A spokesperson for Prestige Biopharma IDC remarked, 'The IDC224 platform is designed not only to enhance the durability of an antibody's therapeutic effect but also to improve ease of administration. We plan to expand the application of this technology to a diverse portfolio of antibody therapeutics in the future.'.

Prestige Biopharma IDC 的发言人表示：“IDC224 平台不仅旨在增强抗体治疗效果的持久性，还致力于提高给药的便利性。我们计划未来将这项技术的应用扩展到多样化的抗体治疗产品组合中。”

About Tuznue®

关于Tuznue®

Tuznue® is a biosimilar of Herceptin® (trastuzumab), developed to offer a more cost-effective therapeutic alternative for patients. It maintains comparable efficacy and safety profiles to the original branded medication. Tuznue® is indicated for the treatment of patients with HER2-positive metastatic breast cancer (MBC), HER2-positive early breast cancer (EBC), and HER2-positive metastatic gastric cancer (MGC)..

Tuznue® 是 Herceptin®（曲妥珠单抗）的生物类似药，旨在为患者提供更具成本效益的治疗选择。它与原研药物保持相当的疗效和安全性。Tuznue® 适用于治疗 HER2 阳性转移性乳腺癌 (MBC)、HER2 阳性早期乳腺癌 (EBC) 和 HER2 阳性转移性胃癌 (MGC) 患者。

About Prestige Biopharma

关于声望生物制药公司

Established in 2015 in Singapore, Prestige Biopharma is a biopharmaceutical company with a diversified portfolio. Among its many pipelines, a first-in-class antibody drug and key biosimilars referencing blockbuster drugs are ongoing clinical development. Notably, the first-in-class PAUF-based antibody drug, Ulenistamab, has received Orphan Drug Designation from the U.S.

总部位于新加坡的 Prestige Biopharma 成立于 2015 年，是一家拥有多元化产品组合的生物制药公司。在其众多研发管线中，一款首创抗体药物和参照重磅药物的关键生物类似药正在进行临床开发。值得注意的是，其首创的基于 PAUF 的抗体药物 Ulenistamab 已获得美国授予的孤儿药资格。

FDA, the European EMA, and the Korean MFDS, along with Fast Track Designation from the U.S. FDA. A global Phase 1/2a clinical trial is currently underway in the United States, Europe, and Asia, with the aim of bringing this innovative therapy to the clinic..

美国食品药品监督管理局（FDA）、欧洲药品管理局（EMA）和韩国食品医药品安全部（MFDS）授予的快速通道资格。目前正在美国、欧洲和亚洲进行一项全球性的1/2a期临床试验，目标是将这种创新疗法引入临床。

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示